Funded Grants

2021

Carla van Herpen, MD, PhD; Radboud University; “PSMA Radioligand Therapy for Salivary Gland Cancer”
Jon Schoenfeld, MD, MPhil, MPH; Dana-Farber Cancer Institute; “Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma”
Kathryn Brayer, PhD, and Scott Ness, PhD; University of New Mexico; “ACC Bioinformatics Project”

2020

Vinod Saladi, PhD; Massachusetts Eye and Ear Institute; “Role of YAP/TEAD and p63 network in ACC”
Liza Makowski, PhD, and Neil Hayes, MD, MS MPH; University of Tennessee HSC; “Targeting T Cell Response in ACC”
Renata Ferrarotto, MD; MD Anderson Cancer Center; “ACC microenvironment and spatial analysis using imaging mass cytometry”
Xiaohong Chen, MD; Beijing Tongren Hospital; “Establishment of xenotransplantation model system for ACC
Yoshitsugu Mitani, DDS, PhD; MD Anderson Cancer Center; “Development of circulating extracellular vesicles as an early biomarker in patients with ACC”
Scott Ness, PhD; University of New Mexico; “Biomarkers for ACC Outcomes”
Evgeny Izumchenko, PhD; University of Chicago; “Organoid development and integrated genomic characterization of ACC”
Paul Swiecicki, MD, PhD; University of Michigan; “Characterization of novel tissue biomarkers in ACC”
Mariana Brait, MSc, PhD; Johns Hopkins University; “Molecular validation of an in vivo model for ACC”
• Jose Javier Bravo-Cordero, PhD; Icahn School of Medicine at Mount Sinai; “Modeling metastatic dissemination of ACC in vivo”
Daniel Pelaez, PhD; University of Miami; “Molecular surveillance of ACC”

2019

Jesse Boehm, PhD; Broad Institute; “ACC Cancer Dependency Map”
Mariana Brait, MSc, PhD; John Hopkins University; and Jose Javier Bravo-Cordero, PhD; Icahn School of Medicine at Mount Sinai; “ACC in vivo model system”
Stephen Doggett, MD; Mission Viejo Hospital; “Brachytherapy in ACC”
Leonard Zon, MD; Boston Children’s Hospital; “ATRA in ACC” (co-funding with the V-Foundation)
Bertrand Baujat, MD, PhD; Sorbonne University; “REFCOR database analysis: ACC
Julia Thierauf, MD; Massachusetts General Hospital/Massachusetts Eye and Ear Institute; “FNA in ACC clinical management”
Adam Fisch, MD, PhD; Massachusetts General Hospital/Massachusetts Eye and Ear Institute; “MYB and MYBL1 IHC in ACC”
Bita Esmaeli, MD, FACS; MD Anderson Cancer Center; “Lacrimal ACC characterization”
Jon Aster, MD, PhD; Brigham and Women’s Hospital; “BCL2 in ACC”
Tatiana Karpinets, PhD and Andrew Futreal, PhD; MD Anderson Cancer Center; “Immune microenvironment and microbiome in ACC”
Alexander Pearson, MD, PhD; University of Chicago; “Deep neural network development in ACC”

2018

Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “ACC Cell Line Banking”
Jon Schoenfeld, MD, MPhil, MPH; Dana-Farber Cancer Institute; “Correlative studies for phase II of Pembrolizumab +/- RT in ACC”
Rogerio Castilho, DDS, MS, PhD; University of Michigan; “HDAC inhibitors plus Cisplatin: mechanisms of action in ACC PDX”
Simon Andreasen, MD, PhD; University of Copenhagen; and Britta Weigelt, PhD; Memorial Sloan Kettering Cancer Center; “Liquid biopsy in ACC”
Robert Ramsay, PhD; University of Melbourne; “MYB cDNA vaccine in ACC”
Angela Koehler, PhD; MIT/Koch Institute; “Advancing chemical probes in ACC”
Scott Ness, PhD; University of New Mexico; and Simon Andreasen, MD, PhD; University of Copenhagen; “Defining ACC subgroups”
Piero Dalerba, MD; Columbia University; “Pharmacological manipulation of cell differentiation in ACC”

2017

Carla van Herpen, MD, PhD; Radboud University; “Radiolabeled PSMA imaging in ACC”
Robert Ramsay, PhD; University of Melbourne; “MYB cDNA vaccine in ACC”
Jon Aster, MD, PhD; Brigham and Women’s Hospital; “NOTCH signature in ACC”

2016

Jens Lohr, MD, PhD; Dana Farber Cancer Institute; “Liquid Biomarkers in ACC”
Nishant Agrawal, MD and Tanguy Seiwart, MD; The University of Chicago Medicine; “Clinical trial correlative studies: PD-1 inhibitor plus chemotherapy”
Piero Dalerba, MD; Columbia University; “Tumor heterogeneity in ACC”
Angela Koehler, PhD; Massachusetts Institute of Technology; “Targeting transcription factors in ACC”
Bhumsuk Keam, PhD; Seoul National University; “Clinical trial correlative studies: axitinib”
Renata Ferrarotto MD; MD Anderson Cancer Center; “ASCO Career Development Award cofunding: NOTCH-related studies”
Robert Metcalf MD, PhD; University of Manchester; “Liquid biomarkers in ACC”
Binbin Li, PhD; Peking University; “ACC Biomarkers and Diagnostics”
Karl-Heinz Klempnauer, PhD; University of Munster; “Distinguished Researcher Award: MYB”
Carlos Caulin, PhD; MD Anderson Cancer Center; “Transgenic mouse model for ACC”
Nikolaus Schultz, PhD; Memorial Sloan Kettering Cancer Center; “ACC Genomic Datasets”
Anna Keiss, MD, PhD; John Hopkins University; “Targeted Radiopharmaceutical Therapy for ACC”
Derrick Lin, MD; Massachusetts Eye and Ear Institute/Massachusetts General Hospital; “ACC Tumor Biorepository and Registry”
Scott Ness, PhD; University of New Mexico; “Screening assay development for ACC”
Mariana Brait, MSc, PhD; John Hopkins University; “ACC Diagnostics”
Robert Ramsay, PhD; University of Melbourne; “MYB cDNA vaccine”

2015

Arturo Sala, PhD; Brunel University; “Transgenic mouse model for ACC”
Seema Agarwal, PhD; Georgetown University; “In vivo model for ACC”
Mary Reyland, PhD and Antonio Jimeno, MD; University of Colorado; “Development of advanced ACC models”
Silvio Gutkind, PhD; University of California San Diego; and Lars Engelhorn, PhD, University of Copenhagen; “Modeling ACC progression and targeted therapies”
Jon Aster, MD, PhD; Brigham and Women’s Hospital; “NOTCH1 sequencing in ACC”
Bradley Bernstein, MD, PhD; Massachusetts General Hospital; “Targeting MYB and epigenetic factors in ACC”
Len Zon, MD; Harvard Stem Cell Institute/Boston’s Children Hospital; “Screening for MYB inhibitors in zebrafish”

2014

Arturo Sala, PhD; Brunel University; “Generating the MYB-NFIB fusion in vitro”
Jon Aster, MD, PhD; Brigham and Women’s Hospital; “Biomarkers in ACC”
Sergey Ivanov, PhD; Yale University; “Targeting cancer stem cells in ACC”
Arturo Sala, PhD; Brunel University; “Assessing MYB-NFIB oncogenic potential in vitro”
Joan Robbins, PhD; Tocagen; “Biomarkers of ACC infectability”
Britta Weigelt, PhD, and Jorge Reis-FIlho, MD, PhD; Memorial Sloan Kettering Cancer Center; “Characterization of MYB-NFIB in ACC of the breast”
Marc Pusztaszeri, MD; Geneva University Hospital; and William Faquin, MD, PhD; Massachusetts Eye and Ear Infirmary; “ACC Diagnostics”
Karl-Heinz Klempnauer, PhD; University of Munster; “Development and screening assays for MYB inhibitors”
Jon Aster, MD, PhD; Brigham and Women’s Hospital; “ACC Diagnostics”
Rogerio Castilho, DDS, MS, PhD; University of Michigan; “Targeting ACC initiating cells”
Adi Gazdar, MD; University of Texas Southwestern; “ACC cell lines”
Frederic Kaye, MD; University of Florida; “ACC cell lines”
Jon Schoenfeld, MD, MPhil, MPH; Dana Farber Cancer Institute; “Immunological markers in ACC”
Seema Agarwal, PhD; Georgetown University; “ACC model systems”
Christopher Moskaluk, MD, PhD; University of Virginia; “MYB co-factors in ACC”

2013

Robert Ramsay, PhD; University of Melbourne; and Goran Stenman, DMD, PhD; University of Gothenburg; “MYB-NFIB fusion mechanism of action in ACC”
Patrick Ha, MD and Nishant Agarwal, MD; John Hopkins University, “ACC sequencing study”
John Bushweller, PhD; University of Virginia; “Screening for MYB inhibitors”
Richard Bakst, MD; Mount Sinai; “Perineural spread in ACC”
Joan Robbins, PhD; Tocagen; “ACC infectability studies”
Tan Ince, MD, PhD; University of Miami; “ACC cell lines”
Michael Barrett, PhD; TGen; “Clinical trial correlative studies: vorinostat”
Timothy Chan, MD, PhD; Memorial Sloan Kettering Cancer Center; “ACC sequencing study”
Kwok Wong, MD, PhD; Dana Farber Cancer Institute; “MYB-NFIB genetically engineered mouse model”
Marc Pusztaszeri, MD; Geneva University Hospital; and William Faquin, MD, PhD; Massachusetts Eye and Ear Infirmary; “ACC Diagnostics”

2012

Scott Ness, PhD; University of New Mexico; “MYB Conference”
Tom Gonda, PhD; University of Queensland; “In vivo models in ACC”
Goran Stenman, DMD, PhD; University of Gothenburg; “1p deletions and receptor tyrosine kinases in ACC”
Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Biobanking, Model Development and Genomics”

2011

Margaret Brandwein-Gensler, MD; University of Alabama, Birmingham; “HPV and ACC”
Kwok Wong, MD, PhD; Dana Farber Cancer Institute; “MYB-NFIB genetically engineered mouse model”
Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Biobanking, Model Development and Genomics”
Wendell Yarbrough, MD, MMHC; Yale University; “TRKC and neurotrophic signaling in ACC”
Scott Ness, PhD; University of New Mexico; “c-MYB variant activity in ACC”
Bradley Bernstein, MD, PhD; Massachusetts General Hospital; “Role of MYB translocation on chromatin landscape in ACC”
Len Zon, MD; Harvard Stem Cell Institute/Boston’s Children Hospital; “Screening for MYB inhibitors in zebrafish”
Lurdes Queimado, MD, PhD; University of Oklahoma; “ACC cell lines”
Jaques Nor, DDS, MS, PhD; University of Michigan; “Stem cells in ACC”

2010

Patrick Ha, MD; John Hopkins University, “Tumor suppressor screen In ACC PDXs”
Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Genomic analysis in ACC”
Timothy Bender, MS, PhD; University of Virginia; “MYB-NFIB fusion proteins in ACC”
Tan Ince, MD, PhD; University of Miami; “ACC cell lines”
Pat LoRusso, DO; Karmanos; “Clinical trial correlative studies: vorinostat”
Christopher Moskaluk, MD, PhD; University of Virginia; “ACC disease pathway analysis”
Andrew Futreal, PhD; Wellcome Trust Sanger Institute; “ACC genomics”
Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “MYB-NFIB fusion gene and screening of ACC”

2009

Goran Stenman, DMD, PhD; University of Gothenburg; “Novel fusions in ACC”
Jason Papin, PhD; University of Virginia; “Bioinformatics systems biology approach to ACC”
Andrew Futreal, PhD; Sanger Institute; “ACC rearrangements”

2008

Mike Rothenburg, MD; Massachusetts General Hospital; “Model development and characterization”
National Institute of Dental and Craniofacial Research; “Salivary Gland Tumor Research: Biorepository and RDCRN”
Mary Pat Moyer, PhD; INCELL; “ACC cell lines”
Patrick Ha, MD; John Hopkins University, “ACC cell lines from PDXs”
John Basile, DDS, DMSc; University of Maryland; “Perineural invasion in ACC”
Claudia Kirsch, MD; University of California, Los Angeles; “3T MRIs and radiologic differentiation in ACC”
Naishuo Zhu, MD, PhD; Fudan University; “Metastasis-related gene function in ACC”
Ed Harlow, PhD; Harvard University; “Genomic screens in ACC”

2007

National Disease Research Interchange; “Rare Disease Biospecimen Alliance”
Andrew Futreal, PhD; Sanger Institute; “ACC sequencing pilot”
Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Biobanking and model development”

2006

Goran Stenman, DMD, PhD; University of Gothenburg; “Genomic imbalances in ACC”

2005

Christopher Moskaluk, MD, PhD; University of Virginia; “Biobanking and model development”